PRKCB and B-cell chronic lymphocytic leukemia: For example, microenvironmental disruption of the CLL niche potentiates the antitumour activity of Ibrutinib, and targeting stromal PKC-β in B-cell lymphomas enhances toxicity to common therapies [120,125].